LIXTE Biotechnology Appoints Sidney Braun As CEO Of Liora Technologies Europe To Lead Expansion Of LiGHT System Proton Therapy And Drive Long-Term Growth

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical and med-tech company focused on advancing cancer treatments, has announced the appointment of Sidney Braun as Chief Executive Officer of its subsidiary, Liora Technologies Europe Ltd. Mr. Braun brings more than twenty years of operational and strategic advisory experience in the healthcare industry, with experience across North America, Europe, and Israel. He played a central role in the creation of Liora and facilitated LIXTE’s acquisition of Liora’s assets from Orbit Capital, Inc. in November 2025.

Throughout his career, Braun has been instrumental in building healthcare networks and infrastructure. He contributed to the development of an infusion network for the biologic drug Remicade, approved for treating multiple immune-mediated inflammatory diseases. He also created a physician network in Canada, which was later acquired by Toronto-based AIM Health Group. In addition to his extensive professional experience, Braun is multi-lingual and holds degrees in economics and business administration from Fordham University.

Geordan Pursglove, CEO of LIXTE, said that Braun’s appointment aligns with the company’s strategy to bring Liora’s LiGHT System technology to the forefront of modern cancer treatment and to support LIXTE’s goal of establishing a recurring revenue model. Pursglove expressed confidence in Braun’s ability to contribute to the organization and to advance the scaling and adoption of an important cancer treatment technology.

Braun commented that leadership in breakthrough medical technology requires building viable, life-changing systems. He stated that he is fully committed to driving further development in the radiotherapy segment of cancer care, with the goal of achieving positive patient outcomes and creating long-term value for LIXTE shareholders.

Liora Technologies is pioneering electronically controlled proton therapy systems designed to treat tumors across various cancer types. Its proprietary flagship technology, the LiGHT System, is intended to provide significant advantages over existing proton therapy technologies, offering precise, controlled treatment options for patients. With Braun leading Liora, LIXTE is positioned to advance its innovative cancer treatment technologies while building operational and strategic capabilities that support long-term growth and improved patient outcomes.